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Mio, and, other causes‘ (18-39 year old patients) with €33.80 Mio. CONCLUSIONS: A
multitude of causes for blindness affects primarily older people. Demographic de-
velopment will lead to an increase in blind people and therefore to a costly public
health problem. Loosing eyesight is connected to high cost on the one hand and to
a lower QOL for patients on the other hand. The analysis shows the high cost of
blindness for the whole society in Austria.
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OBJECTIVES: Blindness represents significant burden of disease worldwide. The
aim of this research is to estimate medical and non medical expenses related to
blindness of elderly patients (60 years) in Hungary so that results can be used for
further policy analyses. METHODS: Inputs for burden of disesase model were de-
rived from the published literature, statistical databases and structured interviews
with relevant experts. We divided the burden of elderly blindness into public and
private medical and non medical costs. In addition to direct costs (social care and
subvention, conduct recourse, medical costs) indirect costs and lost revenues (un-
employment, support to activities of daily living) were also calculated. RESULTS:
The social burden of 6051 elderly blind patients was estimated 53.35 million USD in
2009, 0.03% of the Hungarian GDP (1 USD 128.19 HUF in purchasing power parity
exchange rate). Social care and subventions (20.04 million USD), support to daily
living activities (15.91 million USD) and healthcare costs (6.68 million USD) repre-
sented the largest proportion of expenses. 55% of total burden were derived from
public sector and within public burden social care and subventions represented
two-third of expenses. CONCLUSIONS: The societal burden of elderly blindness is
significant even without measuring its impact on mortality and quality of life. It is
important to redefine the necessary health and social policy objectives of preven-
tion, health care and social integration of elderly blindness. Further research is
needed to measure the impact of medical and non-medical interventions to reduce
the societal burden of elderly blindness
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OBJECTIVES: Retina disease (RD) is a leading cause of blindness in Europe with
significant clinical and economic consequences. The research objective was to
assess the direct health care resource use of patients receiving regular intravitreal
injections (rIVI) to treat RD in France, Spain and the UK (UK). METHODS: Three
focus group sessions were performed with at least 6 retina specialists who treated
RD patients with rIVIs (defined as IVIs every 4 to 6 weeks). A specific questionnaire
assessed resource use including medical visits, diagnostic/monitoring tests and
procedures, drugs administered, IVI adverse event treatment, surgery and trans-
port. Costs were quantified using official and bibliographical sources from each
national health care system perspective over a one-year time horizon. All costs are
expressed in 2010 euros and pound sterling. RESULTS: The annual total direct
health care cost per patient treated with rIVI was €14,725 in France, €10,027 in Spain
and £9,647 to £13,759 in the UK (depending on the setting of care: outpatient or day
case). In all countries, pharmacological costs accounted for the largest proportion
of overall costs (50-80%). Ranibizumab was the most used drug except some coun-
tries that reported off-label use of bevacizumab. Non-pharmacological costs, in-
cluding follow-up visits, tests and administration costs, were €2353, €2918 and
£3000-£9096 in France, Spain and the UK, respectively. CONCLUSIONS: Treatment
with rIVIs is costly to health care systems. While drug costs account for a large
portion of costs, required monitoring is a key cost driver and affects health care
systems’ capacity to treat RD patients. Any strategy to reduce the number of rIVIs
per year would assist in reducing the burden on health care systems. Furthermore,
to assess the full cost of treatment, a study assessing direct cost to patients and
caregivers and indirect cost is also needed.
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OBJECTIVES:Ocular hypertension (OHT) and primary open-angle glaucoma (POAG)
are chronic eye conditions that progress over time, potentially leading to blindness.
Glaucoma management costs increase with disease severity and treatment
switches, drugs and surgical treatments being cost drivers. Our study aimed to
estimate this glaucoma management costs as a function of the disease stage and
the number of treatment changes in Germany. METHODS: We analyzed patient-
level data from an observational study with retrospective collection of medical
resources used by German glaucoma patients over a 5-year period. Associated
costs were derived for drug treatment, medical/surgical procedures, exams/tests
and hospitalizations (Statutory Health Insurance, 2009 costs). A linear regression
was performed on the total management costs and drug costs, with two indepen-
dent variables: the current disease stage (OHT [reference], early, moderate, ad-
vanced POAG), and the number of treatment changes (0 [reference], 1, 2, 3
changes). Costs were estimated against the reference category (OHT-No change).
RESULTS: Data from 154 OHT/POAG patients (57% female, mean age 67 /11
years) was analyzed. OHT patients without treatment change had a mean (SD) total
management cost of €123 (121) per year, which increased by €71 (p0.05), €153
(p0.05) and €398 (p0.004) in disease stages early, moderate and advanced POAG
respectively. Each treatment line change (1, 2, 3) also resulted in increase in cost
of €45 (p0.05), €177 (p0.05) and €451 (p0.0001) compared to the reference cost,
respectively. The drug cost followed the same pattern, with a mean (SD) reference
cost of €83 (33) per year and increases by €70 (p0.05), €88 (p0.022) and €160
(p0.0001) with the disease stage, and €22 (p0.05), €76 (p0.044) and €146
(p0.0001) with each treatment change. CONCLUSIONS: The analysis of observa-
tional data showed a significant increase of the glaucoma management costs with
both the disease severity and the number of treatment changes.
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OBJECTIVES: To estimate the mean annual cost of the different biological agents
licensed for the treatment of patients with moderate to severe plaque psoriasis
during the first year of treatment and maintenance, according to the daily clinical
practice in Spain. METHODS: Data were obtained from case notes of a sequential
patient cohort with psoriasis attending a tertiary referral severe psoriasis service
and initiated on biologics for treatment of their psoriasis at least 12 months before
to the cut-off date (November 2010). Data on drug usage (dose and dosage, starting
and changing dates), that patients have experienced throughout the treatment,
were collected To estimate the annual drug cost for each patient, two periods of
time were considered in the analysis: first year after initiation of biologic therapy
and the year before the cut-off as maintenance period. Specific assumptions re-
garding the dosage, interruption, or switching to other biological after initiation of
treatment were set out. Only the cost of biological agents was considered, regard-
less of any other associated expenses, dismissing those subjects who have been on
therapy less than 3 months before switching to other biological drug.RESULTS:The
primary analysis population comprised a total of 760 patients: adalimumab
(n212), etanercept (n214), infliximab (n145), and ustekinumab (n189). These
subgroups were comparable in age, gender, weight, type of psoriasis, severity, joint
affectation and concomitant diseases prevalence. The mean annual costs were: for
adalimumab 13,346.48 € and 12,120.09 €, etanercept 15,268.28 € and 14,420.46 €,
infliximab 16,589.67€ and 13,889.49 €, and ustekinumab 18.370,50 € and 15.500,44 €.
CONCLUSIONS: The current cost analysis clearly shows that the expenditure as-
sociated with the use of adalimumab both, at the initiation of therapy and main-
tenance, reflects the lowest price charged for a biological drug in patients with
moderate to severe plaque psoriasis, in daily clinical practice in Spain.
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OBJECTIVES: The aim of the study was to analyse and estimate health-related
quality of life (HRQoL), costs of psoriasis during 12 months and disease severity
among patients with psoriasis in Denmark who had received different types of
treatment. METHODS: The study is based on 131 patients included from three
dermatology clinics and data from two different sources; a patient survey and a
retrospective chart review. Information about HRQoL (EQ-5D AND EQ-VAS), Der-
matology Life Quality Index (DLQI), disease severity, resource utilisation in health
care and productivity losses was collected from patient questionnaires. Patient
characteristics and type of treatment were collected from patient records.
RESULTS:During the study period, 16% of the patients used only emollients and/or
topical corticosteroids and 31% used systemic treatment (not biological drugs).
During part of or during the whole 12 months period 53% received biological treat-
ment. Mean direct cost per patient related to in- and out-patient care was esti-
mated to DKK10,682, and indirect cost was DKK9,668. Cost for drugs was DKK88,534
and cost for light treatment was DKK3,775 per patient. Indirect costs were
DKK4,300 for patients with no or minor psoriasis problems and DKK22,000 for
patients with moderate to very severe problems. Light treatment and hospitalisa-
tion costs made up the greatest part in patients receiving local topical treatment.
These costs were also higher in the topical group than in all other treatment
groups. The mean QoL values for all patients were: EQ-5D 0.76, EQ-VAS 74, and DLQI
5.0. The latter value corresponds to “small effect on patient’s life”. Fewer patients
treated with biological drugs experienced problems with treatment than other
treatment groups. CONCLUSIONS: Patients with more extensive psoriasis prob-
lems experienced lower QoL and a larger disease burden. Indirect costs increased
with disease severity. Costs increased with the use of more potent drugs (biological
and systemic drugs).
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OBJECTIVES: To evaluate whether infliximab, a modern off-label biologic, is cost-
effective for treating sarcoid posterior uveitis compared to methotrexate and sys-
temtic steroids. Sarcoid posterior uveitis is a progressive eye disease that can lead
to blindness if untreated. Ophthalmologists have utilized infliximab, a TNF-alpha
inhibitor, which reverses effects of uveitis. METHODS: A semi-Markov model fol-
lowed patients’ therapy from the onset of sarcoid posterior uveitis using the soci-
etal perspective. The lifetime model simulated health states that could lead to
successful reversal of uveitis with standard or intensified treatment with systemic
steroids, methotrexate, or infliximab. Probabilities, health utilities, and costs were
included in the model based on findings from literature. Costs and effects were
discounted at 3% ($US; 2010 values). We conducted univariate sensitivity analyses,
threshold analyses, and a Bayesian multivariate probablistic sensitivity analysis
using 10,000 Monte Carlo simulations. Results were interpretted from a predeter-
mined willingness-to-pay of $50,000/QALY. RESULTS: In order of cost, base case
results showed systemic steroids most affordable ($26,871; 14.58 QALYs), followed
by methotrexate ($40,351; 15.92 QALYs), and then infliximab ($46,547; 15.04
QALYs). Methotrexate was cost-effective compared to steroids, with an incremen-
tal cost-effectiveness ratio of $10,053/QALY. Methotrexate dominated infliximab.
Univariate sensitivity analyses suggested that the model was sensitive to the utility
of a patient’s successful recovery from uveitis (0.84 QALYs). If patients’ health
utility after successful recovery is below 0.750, then infliximab has a greater net
benefit than methotrexate. The multivariate probabilistic sensitivity analysis
showed that methotrexate dominated infliximab in 60% of the simulations.
CONCLUSIONS: This cost-effectiveness analysis suggests that despite major ad-
vances in the use of biologics for treating sight-threatening sarcoid posterior uve-
itis, methotrexate remains a less expensive and more cost-effective strategy. Meth-
otrexate should be adopted as the standard of care for treatment considering its
incremental cost-effectiveness at a reasonable willingness-to-pay. Other thera-
peutic options, such as infliximab, may be considered for certain cases.
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OBJECTIVES: Pharmacoeconomic analyses (PEs) were performed in five European
countries to determine costs, consequences and cost effectiveness of a partially
hydrolysed 100% whey-based infant formula, manufactured by Nestlé S.A, Swit-
zerland (PHF-W) in the prevention of atopic dermatitis (AD) in ‘at risk’ children
when compared to standard cow’s milk formula (SF) or extensively hydrolyzed
formula (EHF). METHODS: The PEs were performed in France, Germany, Spain,
Denmark and Switzerland, using decision-analytic models depicting AD treatment
pathways, as well as resource utilisation and costs associated with the treatment of
AD in healthy yet ‘at risk’ newborns who could not be exclusively breastfed. A time
horizon of 12 months including 6 months of formula consumption was applied,
with country-specific resource use and costs. In four settings, SF was the main
comparator and the final outcome of the PEs was the incremental cost per avoided
case (ICER) of AD when comparing subjects who used PHF-W versus SF. Given a lack
in significant differences in efficacy between PHF-W and EHF, a cost-minimization
approach was used in all settings to compare these formulas. Three perspectives
were applied: the Ministry of Health (MOH), the family and society. RESULTS: The
analyses of PHF-W vs. SF generated ICERs ranging from €801 to €1343 (MOH), from
-€1796 to -€454 (family) and from -€995 to €719 (society). The costs of formula and
time loss were the most important cost drivers. In the analyses of PHF-W versus
EHF in prevention, PHF-W demonstrated savings ranging from €4-€120 million, or
€1.3-€64 million for the MOH perspective. The robustness of the models and the
direction of the results were confirmed by one-way and probabilistic sensitivity
analyses. CONCLUSIONS: In five European countries, PHF-W appears to be the
product best positioned in prevention at a reasonable cost when compared to SF
and with important cost-savings versus EHF.
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OBJECTIVES: To evaluate cost-effectiveness of ustekinumab vs etanercept for se-
vere psoriasis in Russia. METHODS: Cost-effectiveness analysis was performed.
The data about efficacy and safety of biologic agents was analyzed. Cost-effective-
ness ratio (CER) was calculated for ustekinumab and etanercept. Pharmaceutical
costs were taken into account only. Achievement of PASI 75 was a criterion of
efficacy, data about it was extracted from 12 weeks comparative clinical trial.
RESULTS: The efficacy of ustekinumab was higher than etanercept in a direct
comparative trial (67.5 and 56.8% of patients achieved PASI 75 by week 12 respec-
tively). Both biologic agents were generally well tolerated in most patients. Usteki-
numab was a bit less costly than etanercept: 470.00 and 496.62 thousands rub (16.92
and 17.88 thousands $) for 12-weeks treatment respectively. Therefore CER was
more favorable for ustekinumab than for etanercept: 696.30 thousands rub (25.06
thousands $) and 874.33 thousands rub ($31.47 thousands $) per patient with PASI
75 achieved respectively. CONCLUSIONS: Ustekinumab is a dominanting alterna-
tive to etanercept for patients with severe psoriasis in Russia.
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OBJECTIVES: Ozurdex (dexamethasone 700 g intravitreal implant in applicator)
was the first EMA licensed pharmacotherapy for macular oedema following central
and branch retinal vein occlusion (CRVO, BRVO), a leading cause of vision loss. The
objective of this analysis was to evaluate the cost-effectiveness of Ozurdex com-
pared with a strategy of observation for the treatment of macular oedema (ME)
following CRVO, and for BRVO patients with macular haemorrhage (BRVO-MH) or
who have failed prior laser treatment (BRVO-PL). The analysis was performed from
a UK NHS perspective. METHODS: A cost-utility model was developed to estimate
the lifetime costs and effects of Ozurdex compared with observation in patients
with CRVO, BRVO-MH and BRVO-PL based on the GENEVA 008 and GENEVA 009
studies. Patients in the model could move between six BCVA defined health states
(best corrected visual acuity) based on the number of letters read correctly on the
Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Cost data were ob-
tained from literature and NHS reference costs. Utility values ranged between 0.599
and 0.862 and were derived from a preference-based scoring algorithm, the Visual
Function Questionnaire Utility Index (VFQ-UI), valued by members of the general
population using time-trade off (TTO). RESULTS: Ozurdex was shown to be cost-
effective relative to observation with ICERs of £16,522, £17,741 and £6,361 for pa-
tients with CRVO, BRVO-MH and BRVO-PL respectively. One-way sensitivity anal-
ysis demonstrated that the proportion of patients affected in the baseline defined
worse-seeing eye was a key driver of cost-effectiveness. Probabilistic sensitivity
analysis demonstrated that at a threshold of £30,000, Ozurdex was a cost effective
option in 85.2% of simulations for CRVO, 82.1% of simulations for BRVO-MH and
98.2% of simulations for BRVO-PL.CONCLUSIONS:Ozurdex is a cost-effective treat-
ment option from a UK NHS perspective for macular oedema secondary to CRVO,
BRVO-MH and BRVO-PL.
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OBJECTIVES: Ozurdex (dexamethasone 700 g intravitreal implant in applicator)
was the first licensed pharmacotherapy for macular oedema following branch ret-
inal vein occlusion (BRVO) in the UK; however unlicenced use of Bevacizumab
given by intravitreal injection was considered a potential comparator for economic
evaluation. No head to head RCTs exist to compare outcomes; a mixed treatment
comparison (MTC) was performed to synthesise available data. METHODS: A life-
time cost-utility model was produced with a treatment period of up to 3 years.
Patients received an average of 9.96 bevacizumab or 2.24 Ozurdex treatments, 75%
of which were costed based on a day case setting. Efficacy was measured in terms
of letters gained on the Early Treatment of Diabetic Retinopathy Study (ETDRS)
chart. This was estimated from an MTC where the network of evidence included
comparisons of Ozurdex versus observation, observation versus grid laser and grid
laser versus bevacizumab. QALYs were calculated from the letters gained using a
coefficient obtained from regression analysis predicting the Visual Function Ques-
tionnaire Utility Index (VFQ-UI) score from BCVA. Differences in AE profiles were
accounted for within the analysis. RESULTS: The day 180 results of the MTC indi-
cated a difference (pns) in BCVA of 1.74 letters (95% CI -9.57 to 6.19) favouring
bevacizumab; MTC Results at day 60 show this trend to be reversed. The analysis
also demonstrated that an Ozurdex based regimen is less costly than a bevaci-
zumab regimen making the ICER difficult to interpret. Therefore net monetary
benefit (NMB) was calculated to demonstrate an NMB of Ozurdex vs. bevacizumab
(based on day 180 results) of £2,228 at a willingness to pay per QALY of £20,000,
robust to sensitivity analyses. CONCLUSIONS: The results of this analysis indicate
that Ozurdex is a cost-effective treatment for macular oedema following BRVO
when compared with bevacizumab, from a UK NHS perspective.
PSS27
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OBJECTIVES: Cost-effectiveness models in age-related macular degeneration use
the utilities based on the better-seeing eye, because this mainly influence quality of
life. Most models use the utility as if we only treat better-seeing eyes, although in
trials the majority of the treated eyes are the poorer-seeing eyes. This discrepancy
results in overestimating the QALY. Therefore a correction should be applied. The
objective of this study is to estimate the influence on the (incremental) cost-effec-
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